Emerging Treatments for BCG-Unresponsive High-Risk Non-Muscle Invasive Bladder Cancer : Episode 1

Opinion

Video

June 1, 2024

Navigating BCG Shortages in NMIBC

Author(s):

Gordon A. Brown, DO,Siamak Daneshmand, MD

A panel of experts on non–muscle invasive bladder cancer (NMIBC) discuss challenges associated with BCG shortages and the impact on treatment options and patients’ quality of life.

Video Player is loading.

Current Time 0:00

Duration 0:00

Loaded: 0%

Stream Type LIVE

Remaining Time 0:00

EP: 1.Navigating BCG Shortages in NMIBC

EP: 2.The Evolving Treatment Landscape in BCG-Unresponsive NMIBC

EP: 3.Efficacy and Safety Data from SunRISe-1

EP: 4.Overview of the QUILT Trial in BCG-Unresponsive NMIBC

EP: 5.Quality of Life and Progression Considerations in BCG-Unresponsive NMIBC

EP: 6.Adverse Effect Management and the Role of Immunotherapy in NMIBC

EP: 7.Selecting Optimal Treatment in BCG-Unresponsive NMIBC

EP: 8.Patient Monitoring Strategies in BCG-Unresponsive NMIBC

EP: 9.Promising Developments in NMIBC

EP: 10.Key Takeaways on the Evolving NMIBC Treatment Landscape

Related Videos

Human urinary bladder | Image Credit: © magicmine - stock.adobe.com

How recombinant BCG could ease strain of supply issues

Katherine Chan, MD, on viral vs non-viral vectors in bladder cancer

Katherine Chan, MD, on viral vs non-viral vectors in bladder cancer

John Taylor, III, MD, on novel options in NMIBC

John Taylor, III, MD, on novel options in NMIBC

Suzanne B. Merrill, MD, FACS, answers a question during a Zoom video interview

Suzanne B. Merrill, MD, FACS, on EAP program for recombinant BCG

3d rendered illustration - bladder cancer | Image Credit: © Sebastian Kaulitzki - stock.adobe.com

What a long-term study of patients undergoing RARC reveals about upstaging

Sima Porten, MD, on the increased risk of bladder cancer among firefighters

Sima Porten, MD, on the increased risk of bladder cancer among firefighters

Jason Hafron, MD, predicts coming advancements in bladder cancer

Jason Hafron, MD, predicts coming advancements in bladder cancer

Laura Bukavina, MD, on trial of radiation with concurrent sacituzumab govitecan in MIBC

Laura Bukavina, MD, on trial of radiation with concurrent sacituzumab govitecan in MIBC

Chad Reichard, MD, on the Expanded Access Program for recombinant BCG

Chad Reichard, MD, on the Expanded Access Program for recombinant BCG

Neeraja Tillu, MD, answers a question during a Zoom video interview

Neeraja Tillu, MD, discusses predictors of upstaging following RARC for NMIBC

Related Content

Investigational Combination Immunotherapy Treatment for High-Risk, Late-Stage Prostate Cancer Patients Available in Michigan

March 31st 2025

Investigational Combination Immunotherapy Treatment for High-Risk, Late-Stage Prostate Cancer Patients Available in Michigan

Michigan Institute of Urology

Michigan Institute of Urology is a clinical trial site for LEGION-100.

medical depiction of bladder cancer

May 31st 2023

Bladder Cancer Awareness Month: Dr. Kamat highlights the state of bladder cancer care

Urology Times staff

In this episode, Ashish M. Kamat, MD, MBBS, highlights the state of bladder cancer care in recognition of Bladder Cancer Awareness Month.

FDA approves durvalumab/chemo for muscle–invasive bladder cancer

March 28th 2025

FDA approves durvalumab/chemo for muscle–invasive bladder cancer

The approval is supported by results from the phase 3 NIAGARA trial.

Dr. Lutz on sexual dysfunction, performance anxiety, and Peyronie's disease

May 26th 2022

Dr. Lutz on sexual dysfunction, performance anxiety, and Peyronie's disease

Urology Times staff

“We know that erectile dysfunction is really an important issue that can be a harbinger for other underlying cardiovascular or neurological health issues,” says Michael Lutz, MD.

Perioperative outcomes support benefit of TAR-200 plus cetrelimab in MIBC

March 26th 2025

Perioperative outcomes support benefit of TAR-200 plus cetrelimab in MIBC

Andrea Necchi, MD Hannah Clarke

"Provided that we will confirm the efficacy data long-term, there is an opportunity to spare, de-escalate a bit, the treatment in select patients, and to expose the patient with inferior risk of developing severe [adverse] effects," says Andrea Necchi, MD.

Bel-sar shows promising safety, efficacy in NMIBC

March 26th 2025

Bel-sar shows promising safety, efficacy in NMIBC

In patients with intermediate-risk disease, 4 of 5 patients demonstrated a complete response.

Related Content

Bladder Cancer Viewpoints Emerging Treatments for BCG-Unresponsive High-Risk Non-Muscle Invasive Bladder Cancer Michigan Institute of Urology

|

|

Emerging Treatments for BCG-Unresponsive High-Risk Non-Muscle Invasive Bladder Cancer

|

Michigan Institute of Urology

Investigational Combination Immunotherapy Treatment for High-Risk, Late-Stage Prostate Cancer Patients Available in Michigan

March 31st 2025

Investigational Combination Immunotherapy Treatment for High-Risk, Late-Stage Prostate Cancer Patients Available in Michigan

Michigan Institute of Urology

Michigan Institute of Urology is a clinical trial site for LEGION-100.

medical depiction of bladder cancer

May 31st 2023

Bladder Cancer Awareness Month: Dr. Kamat highlights the state of bladder cancer care

Urology Times staff

In this episode, Ashish M. Kamat, MD, MBBS, highlights the state of bladder cancer care in recognition of Bladder Cancer Awareness Month.

FDA approves durvalumab/chemo for muscle–invasive bladder cancer

March 28th 2025

FDA approves durvalumab/chemo for muscle–invasive bladder cancer

The approval is supported by results from the phase 3 NIAGARA trial.

Dr. Lutz on sexual dysfunction, performance anxiety, and Peyronie's disease

May 26th 2022

Dr. Lutz on sexual dysfunction, performance anxiety, and Peyronie's disease

Urology Times staff

“We know that erectile dysfunction is really an important issue that can be a harbinger for other underlying cardiovascular or neurological health issues,” says Michael Lutz, MD.

Perioperative outcomes support benefit of TAR-200 plus cetrelimab in MIBC

March 26th 2025

Perioperative outcomes support benefit of TAR-200 plus cetrelimab in MIBC

Andrea Necchi, MD Hannah Clarke

"Provided that we will confirm the efficacy data long-term, there is an opportunity to spare, de-escalate a bit, the treatment in select patients, and to expose the patient with inferior risk of developing severe [adverse] effects," says Andrea Necchi, MD.

Bel-sar shows promising safety, efficacy in NMIBC

March 26th 2025

Bel-sar shows promising safety, efficacy in NMIBC

In patients with intermediate-risk disease, 4 of 5 patients demonstrated a complete response.

Recent Content

18F-flotufolastat PET/CT shows high inter- and intrareader agreement rates

18F-flotufolastat PET/CT shows high inter- and intrareader agreement rates

Subcutaneous nivolumab under review in EU for solid tumors

Subcutaneous nivolumab under review in EU for solid tumors

FDA approves durvalumab/chemo for muscle–invasive bladder cancer

FDA approves durvalumab/chemo for muscle–invasive bladder cancer

FDA approves expanded label for 177Lu-PSMA-617 in mCRPC

FDA approves expanded label for 177Lu-PSMA-617 in mCRPC

View More Recent Content

Terms and Conditions

Do not sell my Personnal Information

Contact Info

2 Commerce Drive
Cranbury, NJ 08512

© 2025 MJH Life Sciences

All rights reserved.